Awakn Responds to OTC Markets Demand on Recent Promotional Activity

Toronto, Ontario–(Newsfile Corp. – January 14, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company developing and supplying psychedelic therapies (drugs and therapies) to treat addiction, announces that it has been requested by OTC Markets Group Inc. (“OTC Markets”) to issue this statement regarding certain promotional activities regarding its common stock.

On Wednesday, January 12, 2022, OTC Markets informed the Company that it had become aware of certain promotional activities relating to the Company and its common stock traded on the OTCQB Marketplace, including the distribution of promotional emails on January 12, 2022, by third parties discuss the growing ketamine revolution, citing the company’s potential growth in space. Upon review, the Company determined that a third party, who was not engaged by the Company or any of its officers, directors, controlling shareholders or any third party service provider, had distributed promotional emails. The Company had no editorial oversight of promotional materials or opportunity to review prior to distribution; however, the Company has subsequently reviewed the specific Company-related details that were included in these promotional emails and confirmed that these details are factual. The Company wishes to caution readers that statements made in such promotional emails are speculative in nature. For more complete and specific information regarding the Company, its outlook and the risks associated with such outlook, readers should consult the Company’s public filings on SEDAR, its website and other reliable sources. The Company encourages investors to contact their investment advisers before making any investment.

In addition, the Company understands that this promotional activity may have coincided with an increase in trading activity for the Company’s common shares on or about January 5, 2022. The Company does not believe that promotional activities have been a factor in the recent increase in the Company’s trading volume. ordinary actions. Instead, the company attributes the increased trading volume to currently heightened investor interest following its recent press releases which revealed a voluntary blocking agreement from a number of shareholders, l expansion of its ketamine for gambling disorder to include several other behavioral addictions, as well as the release of positive results from the Phase II a/b study of ketamine-assisted therapy for the treatment of gambling-related disorders the use of alcohol.

After investigation by management, none of the Company’s officers, directors or, to the knowledge of the Company, any controlling shareholder or third-party service provider has sold or purchased any common stock of the Company during the past 90 days.

Over the past twelve months, the Company has engaged JRZ Capital (as previously disclosed in a press release dated October 8, 2021), KCSA Strategic Communications for investor and public relations services, and other news outlets , including Investing News Network, Agoracom, InvestorIntel, Just Capital Consulting and The Dales Report.

The Over-the-Counter Markets have further requested the Company to report whether it has issued shares or convertible instruments allowing conversion into equity securities at prices representing a discount to the prevailing market price at the time of the transaction. issue, which the Company did not.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company developing and providing psychedelic therapies (drugs and therapies) to better treat addiction. The Awakn team is made up of world-renowned chemists, scientists, psychiatrists and psychologists who develop and advance the next generation of psychedelic drugs, therapies and enabling technologies to treat addiction. Awakn will deliver these evidence-based psychedelic therapies to clinics in the UK and Europe and through licensing partnerships globally. | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information

This press release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the future performance of the Company. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is planned”, “budget”, “expected”, “estimates”, “continues “, “expects”, “plans”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and expressions or state that certain actions, events or results “may”, “could”, “should”, “should”, “could” or “will” be taken, occur or be carried out, including statements relating to the activities of the Company . All forward-looking statements, including those contained herein, are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in these statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results or developments may differ materially from those indicated in the statements. Certain factors could cause actual results to differ materially from those indicated in the forward-looking information. These include: the Company’s business plans and strategies; the Company’s ability to comply with all applicable government regulations in a highly regulated business; the risks inherent in investing in target companies or projects that have limited or no operating history and that are engaged in activities currently considered illegal in certain jurisdictions; changes in laws; limited operating history; dependence on management; additional funding requirements; competetion; inconsistent public opinion and perception regarding the medical use of psychedelic drugs; and regulatory or policy change. Readers are cautioned that the foregoing list of factors is not exhaustive of factors that could affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release speak only as of the date of this press release or as of the date or dates specified in such statements.

Investors are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking information. For further information on the Company, investors are invited to consult the public documents filed by the Company on SEDAR at The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Investor requests:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media inquiries:
America and Canada: KCSA Strategic Communications
Anne Donohe
[email protected]

Rest of the world: ROAD Communications
Paul Jarman/Anna Ramsey
[email protected]

To view the source version of this press release, please visit